한반도 南部 終末期 櫛文土器와 繩文土器의 年代的 병행관계 검토

Okada Ken Ichi(岡田憲一),Ha In Soo(河仁秀) 한국신석기학회 2009 한국신석기연구 Vol.- No.17

본고의 목적은 동삼동패총에서 출토된 繩文時代 後期土器를 검토 분석함으로써 한 반도 남부 지역 종말기 즐문토기와 승문토기의 연대적 병행관계를 파악하는데 있다. 검토 결과 동삼동패총에서 출토된 2점의 승문토기는 기존에 알려진 승문시대 후기 후엽의 南福寺式토기 등과는 그 형식과 시기를 달리하며, 지금까지 한반도 남해안지 역에서 발견된 승문토기 중 가장 늦은 승문 후기 중엽에서 후엽에 속하는 형식이다. 이것은 기존에 이중구연토기가 연대적으로 승문시대 후기 중엽으로 막연히 인식되어 왔던 사실을 이번 동삼동 출토 승문토기의 분석과 형식 검토를 통해 그 연대를 내 려볼 수 있게 되었음을 의미한다. 또 하나는, 동삼동패총에서 확인된 승문시대 후기 후반 토기가 일본 서북부 구주지 방이 아닌 동북부 구주지방과의 관련을 짐작해 볼 수 있다 점이다. 지금까지 한반도 에서 확인되는 승문시대 후기 전반까지의 토기 요소는 기본적으로 일본 구주의 서북 부 및 중부 구주지방과 관련성이 높은 것으로 추정되어 왔으며, 阿高式, 南福寺式, 사 까나시다식 토기형식이 이를 증명하고 있다. 하지만, 승문시대 후기 중엽 이후가 되면 일변하여 교류대상 지역이 동북부 구주지방으로 전환했을 가능성도 염두에 둘 필요가 있을 것으로 생각된다. 이러한 사실은 한반도 남부와 일본열도와의 교류가 한정된 지 역내에서 만 지속적으로 이루어 진 것이 아니고, 단속적이며 지역적인 관계가 유연하 였음을 반영하는 것으로 추정된다. The study aims to chronological parallel relationships between late chulmun pottery and jomon pottery in the southern Korean peninsula by reviewing and analyzing pottery excavated from Dongsam-dong shell mound in the jomon period. As the results of study, it shows that two pieces of jomon pottery excavated from Dongsam-dong shell mound have different types and times from the previously known late-nanpuguji type pottery in the late jomon period, and they are types involved in the middle-and-late type of the late jomon period, which is latest among jomon pottery which has been found until now in the southern Korean peninsula. In addition, this data can be a clue to analyze parallel relationships of late jomon pottery through the assemblage relations with chulmun pottery. The end of chulmun pottery in the southern Korean peninsula is related with the late mimanda type pottery stage compared to the chronology of jomon pottery in Japan. Through the finding, the fact, that pottery with double mouth rim has been vaguely considered as the middle-pottery of the late jomon period, was examined chronically through an analysis and type review of jomon pottery excavated in Dongsam-dong. On the other hand, the late-pottery, which is excavated from Dongsam-dong shell mound, in the late jomon period is expected to have the relations with Japan’s northeast Kyushu, not with northwest Kyushu. The pottery elements until the beginning of the late jomon pottery, which has been found in the southern Korean peninsula until now, seem to basically have high correlations with Japan’s northwest and central Kyushu, and adagga type pottery, nanpuguji type pottery, and sagganasida type pottery prove this. However, it needs to consider that interchange areas may transfer to the northeast Kyushu by changing completely from the middle of the late jomon period. Based on the fact, it is estimated to reflect that the interchange between the southern Korean peninsula and Japan was not made only in the designated area continuously, and that intermittent and regional relations were flexible.

Structural Design of Nakanoshima Festival Tower

Okada, Ken,Yoshida, Satoshi Council on Tall Building and Urban Habitat Korea 2014 International journal of high-rise buildings Vol.3 No.3

Nakanoshima Festival Tower is a 200 m high-rise complex building which contains a renewed 2700-seat capacity concert hall known as "Festival Hall" and offices including headquarter of a news company. In order to build up an office tower on the hall which requires large open space, a giant truss system is employed. The giant trusses being composed of mega-trusses and belt-trusses support all the building weight above them and transfer the load to the outside of the hall. The building also requires high seismic resistance performance for a news company. Application of mid-story seismic isolation enables the building to satisfy high-level seismic resistance criteria.

Role of Enhanced Visibility in Evaluating Polyposis Syndromes Using a Newly Developed Contrast Image Capsule Endoscope

( Ken Hatogai ),( Naoki Hosoe ),( Hiroyuki Imaeda ),( Jean Francois Rey ),( Sawako Okada ),( Yuka Ishibashi ),( Kayoko Kimura ),( Kazuaki Yoneno ),( Shingo Usui ),( Yosuke Ida ),( Nobuhiro Tsukada ),( 대한소화기학회 2012 Gut and Liver Vol.6 No.2

Background/Aims: A flexible spectral imaging color enhancement system was installed in new capsule software for video capsule endoscopy. Contrast image capsule endoscopy (CICE) is a novel technology using light-emitting diodes selected for the main absorption range of hemoglobin. We assessed the feasibility and diagnostic effi cacy for small bowel surveillance in patients with polyposis syndromes. Methods: Six patients with polyposis syndromes, four with familial adenomatous polyposis and one each with Cowden syndrome (CS) and Cronkhite-Canada syndrome (CCS) were examined using CICE. We conducted three evaluations to assess the effect on the numbers of the detected polyps; compare polyp diagnostic rates between adenoma and hamartoma; and assess polyp visibility. Results: The numbers of detected polyps and diagnostic accuracy did not differ signifi cantly between pre-contrast and contrast images. However, 50% of the adenomatous polyps displayed enhanced visibility on contrast images. CICE contrast images exhibited clearly demarcated lesions and improved the visibility of minute structures of adenomatous polyps. Hamartomatous polyp micro-structures in patients with CS and CCS were more clearly visualized on contrast than pre-contrast images. Conclusions: CICE is an effective tool for enhancing the visibility of polyps in patients with polyposis syndrome. (Gut Liver 2012;6:218-222)

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

Kato, Ken,Cho, Byoung Chul,Takahashi, Masanobu,Okada, Morihito,Lin, Chen-Yuan,Chin, Keisho,Kadowaki, Shigenori,Ahn, Myung-Ju,Hamamoto, Yasuo,Doki, Yuichiro,Yen, Chueh-Chuan,Kubota, Yutaro,Kim, Sung-Ba ELSEVIER 2019 LANCET ONCOLOGY Vol.20 No.11

<P><B>Summary</B></P> <P><B>Background</B></P> <P>Chemotherapy for patients with advanced oesophageal squamous cell carcinoma offers poor long-term survival prospects. We report the final analysis from our study of the immune checkpoint PD-1 inhibitor nivolumab versus chemotherapy in patients with previously treated advanced oesophageal squamous cell carcinoma.</P> <P><B>Methods</B></P> <P>We did a multicentre, randomised, open-label, phase 3 trial (ATTRACTION-3) at 90 hospitals and cancer centres in Denmark, Germany, Italy, Japan, South Korea, Taiwan, the UK, and the USA. We enrolled patients aged 20 years and older with unresectable advanced or recurrent oesophageal squamous cell carcinoma (regardless of PD-L1 expression), at least one measurable or non-measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, a baseline Eastern Cooperative Oncology Group performance status of 0–1, and who were refractory or intolerant to one previous fluoropyrimidine-based and platinum-based chemotherapy and had a life expectancy of at least 3 months. Patients were randomly assigned (1:1) to either nivolumab (240 mg for 30 min every 2 weeks) or investigator's choice of chemotherapy (paclitaxel 100 mg/m<SUP>2</SUP> for at least 60 min once per week for 6 weeks then 1 week off; or docetaxel 75 mg/m<SUP>2</SUP> for at least 60 min every 3 weeks), all given intravenously. Treatment continued until disease progression assessed by the investigator per RECIST version 1.1 or unacceptable toxicity. Randomisation was done using an interactive web response system with a block size of four and stratified according to geographical region (Japan <I>vs</I> rest of the world), number of organs with metastases, and PD-L1 expression. Patients and investigators were not masked to treatment allocation. The primary endpoint was overall survival, defined as the time from randomisation until death from any cause, in the intention-to-treat population that included all randomly assigned patients. Safety was assessed in all patients who received at least one dose of the assigned treatment. This trial is registered with ClinicalTrials.gov, number NCT02569242, and follow-up for long-term outcomes is ongoing.</P> <P><B>Findings</B></P> <P>Between Jan 7, 2016, and May 25, 2017, we assigned 419 patients to treatment: 210 to nivolumab and 209 to chemotherapy. At the time of data cutoff on Nov 12, 2018, median follow-up for overall survival was 10·5 months (IQR 4·5–19·0) in the nivolumab group and 8·0 months (4·6–15·2) in the chemotherapy group. At a minimum follow-up time (ie, time from random assignment of the last patient to data cutoff) of 17·6 months, overall survival was significantly improved in the nivolumab group compared with the chemotherapy group (median 10·9 months, 95% CI 9·2–13·3 <I>vs</I> 8·4 months, 7·2–9·9; hazard ratio for death 0·77, 95% CI 0·62–0·96; p=0·019). 38 (18%) of 209 patients in the nivolumab group had grade 3 or 4 treatment-related adverse events compared with 131 (63%) of 208 patients in the chemotherapy group. The most frequent grade 3 or 4 treatment-related adverse events were anaemia (four [2%]) in the nivolumab group and decreased neutrophil count (59 [28%]) in the chemotherapy group. Five deaths were deemed treatment-related: two in the nivolumab group (one each of interstitial lung disease and pneumonitis) and three in the chemotherapy group (one each of pneumonia, spinal cord abscess, and interstitial lung disease).</P> <P><B>Interpretation</B></P> <P>Nivolumab was associated with a significant improvement in overall survivaland a favourable safety profile compared with chemotherapy in previously treated patients with advanced oesophageal squamous cell carcinoma, and might represent a new standard second-line treatment option for these patients.

A ROUTING METHOD BASED ON REQUIRED COMMUNICATION QUALITIES IN HIGH-SPEED MULTIMEDIA NETWORK

Hideki Tode,Ken Ojiri,Miki Yamamoto,Hironmi Okada,Hiromasa Ikeda 한국통신학회 1995 Asia-Pacific Conference on Communications Vol.2 No.1

Thermal Hazard Evaluation on Self-polymerization of MDI

Sato, Yoshihiko,Okada, Ken,Akiyoshi, Miyako,Murayama, Satoshi,Matsunaga, Takehiro The Korean Society of Safety 2010 International Journal of Safety Vol.9 No.1

Thermal analysis, heating test on gram scale and simulation of exothermic behavior based on kinetic analysis has been conducted in order to evaluate thermal hazards of self-polymerization of MDI. The exothermic reactions of MDI are expected to be the polymerization which forms carbodiimide and carbon dioxide, dimerization and trimerization. When MDI is kept in adiabatic condition during 1 week (10080 hours), the simulated result shows runaway reaction can occur in the case that initial temperature was more than $130^{\circ}C$. The relationship between the initial temperature (T, $^{\circ}C$) and TMR is given in a following equation. TMR=$4.493{\times}10^{-7}$ exp ($9.532{\times}10^3$/(T+273.15)) We propose that the relationship gives important criteria of handling temperature of MDl to prevent a runaway reaction.

Novel mutations of CDKN1C in Japanese patients with Beckwith-Wiedemann syndrome

Hitomi Yatsuki,Ken Higashimoto,Kosuke Jozaki,Kayoko Koide,Junichiro Okada,Yoriko Watanabe,Nobuhiko Okamoto,Yoshinobu Tsuno,Yoko Yoshida,Kazutoshi Ueda,Kenji Shimizu,Hirofumi Ohashi,Tsunehiro Mukai,Hid 한국유전학회 2013 Genes & Genomics Vol.35 No.2

Beckwith-Wiedemann syndrome (BWS) is an imprinting-related human disease that is characterized by macrosomia, macroglossia, abdominal wall defects, and variable minor features. BWS is caused by several genetic/epigenetic alterations, such as loss of methylation at KvDMR1,gain of methylation at H19-DMR, paternal uniparental disomy of chromosome 11, CDKN1C mutations, and structural abnormalities of chromosome 11. CDKN1C is an imprinted gene with maternal preferential expression, encoding for a cyclin-dependent kinase (CDK) inhibitor. Mutations in CDKN1C are found in 40 % of familial BWS cases with dominant maternal transmission and in *5 % of sporadic cases. In this study, we searched for CDKN1C mutations in 37BWS cases that had no evidence for other alterations. We found five mutations—four novel and one known—from a total of six patients. Four were maternally inherited and one was a de novo mutation. Two frame-shift mutations and one nonsense mutation abolished the QT domain, containing a PCNA-binding domain and a nuclear localization signal. Two missense mutations occurred in the CDK inhibitory domain,diminishing its inhibitory function. The above-mentioned mutations were predicted by in silico analysis to lead to loss of function; therefore, we strongly suspect that such anomalies are causative in the etiology of BWS.

The Impact of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

( Manabu Kawai ),( Seiko Hirono ),( Ken-ichi Okada ),( Motoki Miyazawa ),( Yuji Kitahata ),( Ryohei Kobayashi ),( Masaki Ueno ),( Shinya Hayami ),( Hiroki Yamaue ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1

Backgrounds: According to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines, pancreatic ductal adenocarcinoma (PDAC) can be classified as resectable, borderline resectable, or unresectable. Although borderline resectable PDAC (BRPC) may technically be resectable, it has particularly high risks of margin-positive resection and postoperative recurrence. Therefore, preoperative treatment is recommended for BRPC patients in both the NCCN Guidelines and an expert consensus statement. However, the establishment of the most appropriate neoadjuvant therapy is needed by further studies. The aim of these studies is to evaluate the impact of neoadjuvant chemotherapy for BRPC and confirm the safety and efficacy of two regimens of neoadjuvant therapy for BRPC. Our Clinical Trials: First, we evaluated the impact of neoadjuvant chemotherapy for BRPC. 143 BRPC-A patients undergoing pancreatectomy were reviewed from among 330 pancreatic cancer patients, including 111 potentially resectable pancreatic cancer patients and 76 BRPC with portal vein involvement patients. We compared the clinicopathological factors of 40 BRPC-A patients treated with neoadjuvant treatment followed by surgery and those of 103 BRPC-A patients treated with upfront surgery. The R0 rate and progression-free survival of BRPC-A patients who received neoadjuvant therapy and subsequent surgical resection were significantly better compared to those who received upfront surgery (R0: P = 0.041; progression-free survival: P = 0.033), but overall survival was not significantly different. Neoadjuvant treatment followed by surgery might provide clinical benefits for BRPC-A patients; however, the establishment of the most appropriate neoadjuvant treatment is needed by further studies. To evaluate appropriate neoadjuvant treatment, two prospective pilot trials were conducted as follows; modified FOLFIRINOX (without bolus 5-FU and LV, also decreased the dose of irinotecan; FIRINOX) and nab-paclitaxel plus gemcitabine therapy. Modified FOLFIRINOX was given to the first five patients in the 4-cycle group of the regimen and next five patients in the 8-cycle group. The primary end point was the toxicity of the therapy and one of the secondary end points were the optimal duration. The overall rate of grade 3 and 4 events was 80 %: 3 patients (60%) in the four-cycle group and five patients (100%) in the eight-cycle group had grade 3 or 4 adverse events. There was no incidence of serious adverse effect such as febrile neutropenia, sepsis, liver abscess or uncontrollable diarrhea. There was no clinically relevant morbidity presented in patients who underwent surgery. R0 rates by intention to treat were 60.0% in the four-cycle group and 40 % in the eight-cycle group (P = 0.999). The histopathologic treatment effect based on the Evans grade revealed grade I (n = 1), IIa (n = 3) in the four-cycle group and grade I (n = 2), IIa (n = 1) in the eight-cycle group. Nab-paclitaxel plus gemcitabine therapy: the primary endpoint was the toxicity, and secondary endpoints were the resection rate, the R0 resection rate. The overall rate of any grade and grade 3-4 events were 100% and 90%. The majority of these adverse events represented expected neutropenia. The resection and R0 resection rates were 80% and 70%, respectively. Conclusion: FIRINOX therapy was feasible and safe for strictly selected patients with BRPC. On the other hand, nab-paclitaxel plus gemcitabine therapy was safe and feasible without strict selection of patients with BRPC. A multicenter phase II study is in progress to investigate the efficacy of neoadjuvant nab-paclitaxel plus gemcitabine therapy on overall survival (UMIN000024154).

Protective Effect of Betaine Derived from Suger Beet Molasses against D-Galactsamine-Induced Acute Liver Injury in Rats

Sakura Kawakami,Yumi Nakamura,Tomoko Okada,Kyu Ho Han,Kiyoshi Ohba,Tsutomu Aritsuka,Hirokatsu Uchino,Ken-ichiro Shimada,Mitsuo Sekikawa,Michihiro Fukushima 한국식품영양과학회 2012 한국식품영양과학회 학술대회발표집 Vol.2012 No.10

Chronic obstructive pulmonary disease severity in middle-aged and older men with osteoporosis associates with decreased bone formation

Manabu Tsukamoto,Toshiharu Mori,Eiichiro Nakamura,Yasuaki Okada,Hokuto Fukuda,Yoshiaki Yamanaka,Ken Sabanai,Ke-Yong Wang,Takeshi Hanagiri,Satoshi Kuboi,Kazuhiro Yatera,Akinori Sakai 대한골다공증학회 2020 Osteoporosis and Sarcopenia Vol.6 No.4

Objectives: Chronic obstructive pulmonary disease (COPD) is a risk factor for osteoporosis. Nevertheless, much remains unclear regarding the bone metabolism dynamics associated with COPD. The present study focuses on the associations between the COPD severity and serum bone metabolism biomarkers. Methods: We enrolled 40 patients who visited the orthopedics departments at our institutions and underwent dual-energy X-ray absorptiometry between September 2015 and December 2017. Only male osteoporosis patients over 45 years of age were included, and 5 patients were excluded due to disease or use of internal medicines affecting bone metabolism. All subjects underwent lung function testing, spine radiography, and blood tests. We measured percent forced expiratory volume in 1 second (%FEV1), which reflects COPD severity, and we examined the relationships between %FEV1 and serum levels of bone metabolism biomarkers. Results: All subjects were diagnosed with osteoporosis based on T-scores. %FEV1 correlated with body weight, body mass index (BMI), and Z-score/T-scores. %FEV1 moderately correlated with serum levels of alkaline phosphatase (ALP), procollagen type 1 N-terminal propeptide (P1NP), and tartrate-resistant acid phosphatase 5b in the partial correlation analysis adjusted for BMI or T-score in the lumbar vertebrae. We performed a hierarchical multiple regression analysis to identify that serum ALP and P1NP were the independent explanatory variables to %FEV1 independent of other factors. Conclusions: The data suggest that the COPD severity in middle-aged and older men with osteoporosis associates with decreased bone formation. COPD patients may exhibit bone metabolism dynamics characterized by low bone turnover with osteogenesis dysfunction as COPD becomes severe.